PATENT COOPERATION TREATY REC'D 30 JAN 2006

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	т	See Form PCT/IPEA/416		
Applicant's or agent's file reference	FOR FURTHER ACTION	41.6000		
15513-1PCT International application No.	International filing date (day/month	hlyear) Priority date (day/month/year)		
	27 Sentember 2004 (27.09.2004)	25 September 2003 (25.09.2003)		
PCT/US04/31743 27 September 2504 (27:00 PCT/US04/31743				
TRC(8): A 61P 25/00, 25/18, 25/22, 25/2	4, 15/00, 15/10; A61K 31/496, 31/506	5, 31/33; C07D 209/00, 209/04 and G5 Gm		
427, 254.09, 678; 348/330, 410, 405				
Applicant				
CENOMED, INC.	discal maliminary examination	report, established by this International Preliminary he applicant according to Article 36.		
mining Authority line	ier Article 33 and transmisses			
2. This REPORT consists of	of a total of 2 sheets, including t	his cover sheet.		
a This report is also accon	panied by ANNEXES, comprising	ng:		
	International Rure	eau) a total of sheets, as ionows.		
a. (sent to the applicant and to the International Bureau) a total of sheets, as follows: Sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). Sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box. Sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))				
, containing a sequence listing and of the indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains in	dications relating to the following	Hours.		
Box No. I	Basis of the report			
Box No. II	Priority etc. at a standard industrial			
Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
Box No. IV	Lack of unity of invention			
Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement			
Box No. VI	Certain documents cited			
Box No. VII	Certain defects in the international application			
Box No. VIII	Certain observations on the international application			
Date of submission of the dema	ind	Date of completion of this report		
	2	2 December 2005 (22.12.2005)		
10 August 2005 (10.08.2005) Name and mailing address of the I Mail Stop PCT, Atta: IPEA		without Jaulence for Jaulence for		
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 223 13	1	Telephone No. (571) 272.1600		
Facsimile No. (571) 273-3201				

Form PCT/IPEA/409 (cover sheet)(April 2005)

INTERNATIONAL	PRELIMINARY REPORT ON PATENTABILI	ľŢ
TI 4 T TOY OF 14		

International application	No.
PCT/US04/31743	

INTERNATIONAL PRELIMINARY RESPONDE	TCH Obs 2011		
ox No. I Basis of the report			
With regard to the language, this report is based on:	o filed		
in the language in William was	S a translation furnished for the		
the international application in the language of the international application into English.	which is the language of a translation furnished to		
numoses of:			
international search (under Rules 12.3 and 23.1(b))			
publication of the international application (under Ru	ale 12.4(a))		
integrational preliminary examination (under Rules 55.2(a) and/or 53.3(a))			
 With regard to the elements of the international application, this report to the receiving Office in response to an invitation under Article 14 and annexed to this report): 	t table hove been illitistica		
the international application as originally filed/furnished			
the description:			
pages 1-30 as originally filed furnished			
pages* NONE received by this Authority on pages* NONE received by this Authority on			
the claims: pages 31-34 pages* NONE	statement) under Article 19		
the drawings:			
pages NONE as originally filed furnished			
pages* NONE received by this Authority on _			
pages* NONE received by the pages a sequence listing and/or any related table(s) - see Supp	olemental Box Relating to Sequence Listing.		
a sequence listing and/or any related table(s) - see Supp	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
3. The amendments have resulted in the cancellation of:			
NONE			
57			
NONE.			
(special content of the sequence listing (special content of the sequence content of the se	ecify): NONE		
1	ments annexed to this report and listed below had not been made to as filed, as indicated in the Supplemental Box (Rule 70.2(c)).		
the description, pages			
the description, pages the claims, Nos			
1 to / fr cm			
the drawings, sneets/rigs the sequence listing (specify): any table(s) related to the sequence listing (specify):			
* If item 4 applies, some or all of those sheets may be marked	d "superseded."		
* If item 4 applies, some of all of these states			

Form PCT/IPEA/409 (Box No. I) (April 2005)

INTERNATIONAL PRELIMINARY REPORT ON PATENTA	BILITY
---	--------

International application No.
PCT/US04/31743

Box No. V Reasoned statement under Art applicability; citations and exp	ticle 35(2) with regard to n planations supporting such	ovelty, inventive step or industrial statement
Statement Novelty (N)	Claims <u>1-18</u> Claims <u>NONE</u>	
Inventive Step (IS)	Claims <u>1-18</u> Claims <u>NONE</u>	YES NO
Industrial Applicability (IA)	Claims <u>1-18</u> Claims <u>NONE</u>	

2. Citations and Explanations (Rule 70.7)
Claims 1-18 meet the criteria set out in PCT Article 33(2) and (3), because the prior art does not teach or fairly suggest the instant compositions comprising a compound having formula (I).

The prior art reference, FICK et al (WO 03/011396) teach pharmaceutical compositions comprising tetrahydroindolone derivatives linked to arylpiperazines derivatives similar to compound of formula (I) of the instant invention. See page 12, page 16, paragraph [0056] - page 21. FICK also teaches the use of these pharmaceutical compositions for the treatment of psychiatric and neurological diseases. See page 32, paragraph [0108]. However, FICK et al. teaches R6 as H and does not specifically teach R6 (i.e. para substituent) on the arylpiperazine as alkyl, halo, alkoxy, perfluoralkyl, perfluoroalkoxy, or nitro.

Claims 1-18 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.